166 related articles for article (PubMed ID: 36508298)
21. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Utility of Tumor Stage versus American Thyroid Association Risk Class in Thyroid Cancer.
Abiri A; Pang J; Prasad KR; Goshtasbi K; Kuan EC; Armstrong WB; Haidar YM; Tjoa T
Laryngoscope; 2023 Jan; 133(1):205-211. PubMed ID: 35716358
[TBL] [Abstract][Full Text] [Related]
23. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer.
Zanella AB; Scheffel RS; Nava CF; Golbert L; Laurini de Souza Meyer E; Punales M; Gonçalves I; Dora JM; Maia AL
Thyroid; 2018 Oct; 28(10):1285-1292. PubMed ID: 30129889
[TBL] [Abstract][Full Text] [Related]
24. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
25. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
Grani G; Zatelli MC; Alfò M; Montesano T; Torlontano M; Morelli S; Deandrea M; Antonelli A; Francese C; Ceresini G; Orlandi F; Maniglia CA; Bruno R; Monti S; Santaguida MG; Repaci A; Tallini G; Fugazzola L; Monzani F; Giubbini R; Rossetto R; Mian C; Crescenzi A; Tumino D; Pagano L; Pezzullo L; Lombardi CP; Arvat E; Petrone L; Castagna MG; Spiazzi G; Salvatore D; Meringolo D; Solaroli E; Monari F; Magri F; Triggiani V; Castello R; Piazza C; Rossi R; Ferraro Petrillo U; Filetti S; Durante C
Thyroid; 2021 Feb; 31(2):264-271. PubMed ID: 32475305
[No Abstract] [Full Text] [Related]
26. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
27. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.
Tam S; Boonsripitayanon M; Amit M; Fellman BM; Li Y; Busaidy NL; Cabanillas ME; Dadu R; Sherman S; Waguespack SG; Williams MD; Goepfert RP; Gross ND; Perrier ND; Sturgis EM; Zafereo ME
Thyroid; 2018 Oct; 28(10):1301-1310. PubMed ID: 30141373
[TBL] [Abstract][Full Text] [Related]
28. Survival in Papillary Thyroid Microcarcinoma: A Comparative Analysis Between the 7th and 8th Versions of the AJCC/UICC Staging System Based on the SEER Database.
Yang F; Zhong Q; Huang Z; Lian M; Fang J
Front Endocrinol (Lausanne); 2019; 10():10. PubMed ID: 30733707
[No Abstract] [Full Text] [Related]
29. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
30. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
31. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer.
Redlich A; Luster M; Lorenz K; Lessel L; Rohrer TR; Schmid KW; Frühwald MC; Vorwerk P; Kuhlen M
J Clin Endocrinol Metab; 2022 Jan; 107(1):e165-e177. PubMed ID: 34415989
[TBL] [Abstract][Full Text] [Related]
32. Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.
Kim K; Kim JK; Lee CR; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY
Ther Adv Endocrinol Metab; 2020; 11():2042018820921019. PubMed ID: 32489582
[TBL] [Abstract][Full Text] [Related]
33. Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer: Is Total Thyroidectomy Necessary for Patients at Any Risk?
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Ito K
Thyroid; 2020 Apr; 30(4):548-556. PubMed ID: 31910105
[No Abstract] [Full Text] [Related]
34. The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.
Verburg FA; Mäder U; Luster M; Reiners C
Clin Endocrinol (Oxf); 2018 Jun; 88(6):950-956. PubMed ID: 29573277
[TBL] [Abstract][Full Text] [Related]
35. A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study.
Grani G; Gentili M; Siciliano F; Albano D; Zilioli V; Morelli S; Puxeddu E; Zatelli MC; Gagliardi I; Piovesan A; Nervo A; Crocetti U; Massa M; Samà MT; Mele C; Deandrea M; Fugazzola L; Puligheddu B; Antonelli A; Rossetto R; D'Amore A; Ceresini G; Castello R; Solaroli E; Centanni M; Monti S; Magri F; Bruno R; Sparano C; Pezzullo L; Crescenzi A; Mian C; Tumino D; Repaci A; Castagna MG; Triggiani V; Porcelli T; Meringolo D; Locati L; Spiazzi G; Di Dalmazi G; Anagnostopoulos A; Leonardi S; Filetti S; Durante C
J Clin Endocrinol Metab; 2023 Jul; 108(8):1921-1928. PubMed ID: 36795619
[TBL] [Abstract][Full Text] [Related]
36. Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis.
Kim M; Kim WG; Jeon MJ; Kim HK; Yi HS; Kim ES; Kim BH; Kim WB; Shong YK; Kang HC; Kim TY
Endocrinol Metab (Seoul); 2020 Mar; 35(1):149-156. PubMed ID: 32207275
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the use of a two-step age-based cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer.
van Velsen EFS; Peeters RP; Stegenga MT; Mäder U; Reiners C; van Kemenade FJ; van Ginhoven TM; Visser WE; Verburg FA
Eur J Endocrinol; 2022 Feb; 186(3):389-397. PubMed ID: 35038308
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Implication of N1b Classification in the Eighth Edition of the Tumor-Node-Metastasis Staging System of Differentiated Thyroid Cancer.
Kim M; Jeon MJ; Oh HS; Park S; Song DE; Sung TY; Kim TY; Chung KW; Kim WB; Shong YK; Lee YM; Kim WG
Thyroid; 2018 Apr; 28(4):496-503. PubMed ID: 29620964
[TBL] [Abstract][Full Text] [Related]
40. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.
Luster M; Aktolun C; Amendoeira I; Barczyński M; Bible KC; Duntas LH; Elisei R; Handkiewicz-Junak D; Hoffmann M; Jarząb B; Leenhardt L; Musholt TJ; Newbold K; Nixon IJ; Smit J; Sobrinho-Simões M; Sosa JA; Tuttle RM; Verburg FA; Wartofsky L; Führer D
Thyroid; 2019 Jan; 29(1):7-26. PubMed ID: 30484394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
